BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32268350)

  • 21. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
    Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
    Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study.
    Moratto D; Giliani S; Bonfim C; Mazzolari E; Fischer A; Ochs HD; Cant AJ; Thrasher AJ; Cowan MJ; Albert MH; Small T; Pai SY; Haddad E; Lisa A; Hambleton S; Slatter M; Cavazzana-Calvo M; Mahlaoui N; Picard C; Torgerson TR; Burroughs L; Koliski A; Neto JZ; Porta F; Qasim W; Veys P; Kavanau K; Hönig M; Schulz A; Friedrich W; Notarangelo LD
    Blood; 2011 Aug; 118(6):1675-84. PubMed ID: 21659547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging treatment options for Wiskott-Aldrich syndrome.
    Worth AJ; Thrasher AJ
    Expert Rev Clin Immunol; 2015; 11(9):1015-32. PubMed ID: 26159751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
    Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
    Nishimura A; Aoki Y; Ishiwata Y; Ichimura T; Ueyama J; Kawahara Y; Tomoda T; Inoue M; Matsumoto K; Inoue K; Hiroki H; Ono S; Yamashita M; Okano T; Tanaka-Kubota M; Ashiarai M; Miyamoto S; Miyawaki R; Yamagishi C; Tezuka M; Okawa T; Hoshino A; Endo A; Yasuhara M; Kamiya T; Mitsuiki N; Ono T; Isoda T; Yanagimachi M; Tomizawa D; Nagasawa M; Mizutani S; Kajiwara M; Takagi M; Kanegane H; Imai K; Morio T
    J Clin Immunol; 2021 Jul; 41(5):944-957. PubMed ID: 33527309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful allogeneic peripheral blood stem cell transplantation in Wiskott-Aldrich Syndrome Patients: first report in Thailand.
    Hongeng S; Benjaponpitak S; Tardtong P; Varavithya W; Chuansumrit A; Chunharas A; Chaisiripoomkere W; Hathira P
    Asian Pac J Allergy Immunol; 2001 Sep; 19(3):191-5. PubMed ID: 11826914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene.
    Oshima K; Imai K; Albert MH; Bittner TC; Strauss G; Filipovich AH; Morio T; Kapoor N; Dalal J; Schultz KR; Casper JT; Notarangelo LD; Ochs HD; Nonoyama S
    J Clin Immunol; 2015 Jan; 35(1):15-21. PubMed ID: 25388447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haploidentical bone marrow transplantation in a pediatric patient with Wiskott-Aldrich syndrome. A case report.
    Pury S; López Orozco M; Pichichero G; Sasia LV; Morell D; Álvarez MS; Basquiera AL; Mas ME; Salvucci K
    Arch Argent Pediatr; 2024 Feb; 122(1):e202310061. PubMed ID: 37471507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unrelated umbilical cord stem cell transplantation in an eleven-month-old male infant with Wiskott-Aldrich syndrome.
    Chen CY; Chiou YH; Su HW; Chang YH
    Kaohsiung J Med Sci; 2018 Feb; 34(2):122-123. PubMed ID: 29413229
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
    Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.